ライフサイエンスコーパス: donepezil

1 course of the acetylcholinesterase inhibitor donepezil.

2 attenuation by the AChE-selective inhibitor donepezil.

3 events or deaths, or between 5 mg and 10 mg donepezil.

4 i) displaying better brain/plasma ratio than donepezil.

5 oxicity than the FDA-approved standard drug, Donepezil.

6 the reversible acetylcholinesterase blocker donepezil.

7 d rats, which was significantly increased by donepezil.

8 higher than that of the standard inhibitor, donepezil (0.061 +/- 0.009 ug/mL), indicating considerab

9 mals and the acetylcholinesterase inhibitor, donepezil (1 mg/kg), protected against the acute cogniti

10 months of age for 6 months of treatment) of donepezil (1, 2, 4 mg/kg, in drinking water) on tissue a

11 that include their prescribed dosage ranges, donepezil (1-1000 nM) and galantamine (50-1000 nM) incre

12 d start memantine 20 mg per day, or continue donepezil 10 mg per day and start memantine 20 mg per da

13 of 12-19), and had been stably treated with donepezil 10 mg per day for 3 or more months.

14 Scotland and randomly allocated to continue donepezil 10 mg per day without memantine, discontinue d

15 Patients were randomly assigned to receive donepezil 5 mg or placebo orally every morning for 7 day

16 AD patients before and after treatment with donepezil (5 and 10 mg/day) for at least 5 weeks and com

17 were obtained before and after taking either donepezil (5 mg) or a placebo (lactose) pill.

18 disease received 24 weeks of treatment with donepezil (5 mg/day for the first 28 days and 10 mg/day

19 period in which they were randomly allocated donepezil (5 mg/day) or placebo.

20 eted this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind

21 After stabilization on donepezil (5.7 +/- 1.7 weeks at 10 mg) patients showed i

22 5) for rivastigmine to -2.17 for 10 mg daily donepezil (95% CI -2.98 to -1.35).

23 Consistently, systemic treatment with donepezil, a centrally active acetylcholinesterase inhib

24 Donepezil, a cholinesterase inhibitor, restored performa

25 Prior studies have suggested that donepezil, a neurotransmitter modulator, may improve cog

26 5-(11)C-methoxy-donepezil, a noncompetitive acetylcholinesterase ligand,

27 II study was conducted to determine whether donepezil, a US Food and Drug Administration-approved re

28 combination of donepezil and memantine over donepezil alone.

29 Donepezil also reduced response amplitude in visual cort

30 The dose of 4 mg/kg of donepezil also significantly increased synaptic density

31 Donepezil, an acetylcholinesterase inhibitor, is an appr

32 and (2) a pharmacological intervention using donepezil, an acetylcholinesterase inhibitor.

33 E, alone and in complexes with drug ligands; donepezil, an Alzheimer's disease drug, binds differentl

34 articipants (10% [95% CI, 0%-21%]) receiving donepezil and 9 of 27 participants (33% [95% CI, 16%-51%

35 Donepezil and antidepressant therapy temporarily improve

36 behavior of VAChTcKO mice was alleviated by donepezil and by l-DOPA, confirming an acetylcholine/dop

37 ophoric features of cholinesterase inhibitor donepezil and diarylthiazole as potential multitarget-di

38 levels and Ki values for AChE inhibition for donepezil and galantamine in rat, mouse, and rabbit afte

39 are acetylcholinesterase inhibitors, such as donepezil and galantamine.

40 pport slightly different modes of action for donepezil and galantamine.

41 ine from the brain is in general faster that donepezil and is faster in rabbits compared to rats and

42 randomised, double-blind, placebo-controlled Donepezil and Memantine in Moderate to Severe Alzheimer'

43 o significant benefits of the combination of donepezil and memantine over donepezil alone.

44 al cognition (n = 73) showed no benefit with donepezil and no increase in recurrence of major depress

45 The efficacy of donepezil and of memantine did not differ significantly

46 sity improved significantly on day 8 in both donepezil and placebo groups.

47 no significant differences were seen between donepezil and placebo in behavioural and psychological s

48 eta-analysis indicated beneficial effects of donepezil and rivastigmine for cognitive and psychiatric

49 nue donepezil without memantine, discontinue donepezil and start memantine 20 mg per day, or continue

50 l without memantine, 76 (26%) to discontinue donepezil and start memantine, and 73 (25%) to continue

51 onepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and

52 e donepezil and start memantine, or continue donepezil and start memantine.

53 nd start memantine, and 73 (25%) to continue donepezil and start memantine.

54 tarted memantine, and 43 [59%] who continued donepezil and started memantine).

55 without memantine, 41 [54%] who discontinued donepezil and started memantine, and 43 [59%] who contin

56 ffects of continuation or discontinuation of donepezil and starting of memantine on subsequent nursin

57 ignificant difference between the effects of donepezil and those of placebo on the basis of the chang

58 In contrast, donepezil and xanomeline increased time awake in rodents

59 rmacologically elevated cholinergic (through donepezil) and catecholaminergic (through atomoxetine) l

60 The combination of 5al, donepezil, and memantine (triple combination) produces s

61 The cholinesterase inhibitors rivastigmine, donepezil, and metrifonate, which are devoid of nicotini

62 In cognitively intact patients, donepezil appears to have no clear benefit for preventin

63 The cholinesterase inhibitor, donepezil (Aricept), reverses AIE effects on dendritic s

64 rent AD therapeutics memantine (Namenda) and donepezil (Aricept), using similar doses for each, revea

65 Administration of the 4 mg/kg dose of donepezil, as compared to vehicle and lower doses of don

66 Patients assigned to continue donepezil, as compared with those assigned to discontinu

67 r's disease, we report herein a new class of donepezil-based "bio-oxidizable" prodrugs 1 designed to

68 imination task, once while ingesting 5 mg of donepezil before every training session and once while p

69 Autoradiography showed high (11)C-donepezil binding (dissociation constant, 6-39 nM) in pi

70 We also demonstrated high (11)C-donepezil binding in bacterial abscesses.

71 We detected significantly decreased (11)C-donepezil binding in the small intestine (-35%; P = 0.00

72 Decreases in (11)C-donepezil binding may, therefore, represent a marker of

73 g affinities and levels of nonspecific (11)C-donepezil binding to porcine tissues.

74 After donepezil, cerebral cortical inhibition in AD brain aver

75 ignificant associations between memantine or donepezil compared with other dementia medications and t

76 To evaluate the effectiveness of donepezil compared with placebo in cancer patients with

77 No significant benefits were seen with donepezil compared with placebo in institutionalisation

78 The adjusted hazard ratio (HR) for donepezil compared with rivastigmine or galantamine (coh

79 .09 [95% CI 1.29-3.39]) than in the combined donepezil continuation groups, and no difference during

80 Alzheimer's disease (who had been prescribed donepezil continuously for at least 3 months at a dose o

81 receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years.

82 Cholinergic enhancement with donepezil decreased the spatial spread of excitatory fMR

83 In contrast, the cholinergic agent donepezil did not measurably affect arousal or the curve

84 ylcholinesterase inhibitors rivastigmine and donepezil did not potentiate nAChR-mediated responses, w

85 Treatment with donepezil did not significantly improve the overall comp

86 more nursing home placements in the combined donepezil discontinuation groups during the first year (

87 unction]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or

88 ting better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil

89 Clinical trials of this donepezil dose schedule are not testing the effect of ne

90 hibition, 3-15 times higher galantamine than donepezil doses are needed.

91 All patients were offered open-label donepezil during the second week.

92 potentially worth further exploration (e.g., donepezil, epoetin alfa); (3) drugs with alternative bio

93 -dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or

94 sent study, we explored the utility of (11)C-donepezil for imaging acetylcholinesterase densities in

95 es an acetylcholinesterase inhibitor such as donepezil for mild to severe dementia, and memantine (us

96 ons of a mixture of seven PSYCs (citalopram, donepezil, gabapentin, methamphetamine, sertraline, tram

97 cations approved to treat Alzheimer disease (donepezil, galantamine, rivastigmine, and memantine) imp

98 d dexterity (P < .001), with the benefits of donepezil greater for those who were more cognitively im

99 dence interval, 0.74 to 1.41; P=0.91) or the donepezil group (hazard ratio, 0.80; 95 percent confiden

100 ly assigned to treatment, 47 patients in the donepezil group and 56 in the placebo group were assessa

101 e risk of entering institutional care in the donepezil group compared with placebo was 0.97 (95% CI 0

102 that as compared with the placebo group, the donepezil group had a reduced likelihood of progression

103 e placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the

104 The donepezil group was more likely than the placebo group t

105 nificant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inve

106 improvement in speech comprehension, whereas donepezil had a negative effect.

107 Only 5 mg daily donepezil had an effect on the Clinicians' Global Impres

108 compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by a

109 We examined the effects of donepezil hydrochloride (Aricept) on cognition and brain

110 eports state that widely prescribed doses of donepezil hydrochloride provide nearly complete inhibiti

111 up to 3 nM), outperforming the standard drug donepezil (IC50 = 11 nM), most of the corresponding 1,4-

112 reatment in patients with AD, the effects of donepezil, if any, on the AD process are not known.

113 g the acetylcholinesterase inhibitor (AChEI) donepezil improved attention during visual search at dos

114 nhancement with the cholinesterase inhibitor donepezil improved target detection, and modeling sugges

115 , placebo-controlled study on the effects of donepezil in 27 older adults with mild memory deficits.

116 Withdrawal of donepezil in patients with moderate-to-severe Alzheimer'

117 n vivo by the acetylcholinesterase inhibitor donepezil in rhesus monkeys and healthy volunteers, cons

118 The physostigmine, rivastigmine, and donepezil inhibition activities toward the butyrylcholin

119 from in vitro biochemical tests suggest that donepezil is 40- to 500-fold more potent than galantamin

120 Donepezil is a high-affinity ligand for acetylcholineste

121 Donepezil is not cost effective, with benefits below min

122 The efficacy of donepezil is well known for improving the cognitive perf

123 proposed biologically reassembled nanodrugs, donepezil-loaded apolipoprotein A-I-reconstituted HDL (r

124 In this study, donepezil-loaded PLGA and PLA microspheres (Dp-PLGA-M/Dp

125 ison with the acetylcholinesterase inhibitor donepezil, M(1)/M(4) agonist xanomeline (in NHPs), and M

126 These results suggest that a higher dose of donepezil may have a measurable impact on tissue level o

127 These preliminary results suggest that donepezil may have a potentially protective effect in Al

128 ts, stronger than those of the approved drug donepezil, may pave the way for the use of selenotriazin

129 ment groups did not differ on HVLT-R scores (donepezil mean = 25.98, placebo = 26.50, P = .32).

130 erate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better ou

131 used in patients with memory impairment (eg, donepezil, memantine, and ginkgo biloba), and bone marro

132 however, co-treatment with AD therapeutics (Donepezil, Memantine, Rolipram and Saracatinib) correcte

133 or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point;

134 ted mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence

135 ) postchemotherapy were randomly assigned to donepezil (n = 140) or placebo (n = 136).

136 effect of the acetylcholinesterase inhibitor donepezil on magnetic resonance markers of neurodegenera

137 nce (95% CI -1.74 to -0.16) with 10 mg daily donepezil on the Alzheimer's Disease Functional Assessme

138 a the acetylcholinesterase inhibitor (AChEI) donepezil, on the binocular visual system.

139 e, were randomly assigned to receive 5 mg of donepezil once daily for 6 weeks titrated to 10 mg once

140 randomly assigned to 24 weeks of 5-10 mg of donepezil once daily, did not perform differently at the

141 als from each group were treated with either donepezil or isovolumetric water (i.g.) once daily for f

142 se (5 mg for 6 weeks, 10 mg for 18 weeks) of donepezil or placebo.

143 while subjects were on a 10mg daily dose of donepezil or placebo.

144 intenance antidepressant pharmacotherapy and donepezil or to maintenance antidepressant pharmacothera

145 Two hours after the last donepezil or water dose animals were sacrificed and brai

146 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years.

147 social treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patient

148 We propose that (11)C-donepezil PET imaging may be able to quantify the parasy

149 (11)C-donepezil PET is suitable for imaging acetylcholinestera

150 for modeling uptake kinetics in future (11)C-donepezil PET studies.

151 We used 11C-donepezil PET/CT to assess cholinergic (parasympathetic)

152 Using 5-[(11)C]-methoxy-donepezil positron emission tomography, we studied 12 pa

153 We aimed to determine whether donepezil produces worthwhile improvements in disability

154 acetylcholine (ACh) via the cholinergic drug donepezil reduces the extent to which the eyes compete f

155 le scores were improved after treatment with donepezil, relative to placebo, at weeks 6, 12, 18, and

156 ic dysfunction amelioration after controlled donepezil release.

157 of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1 and 2.3 microg/g in rat

158 he brain-to-plasma ratio for galantamine and donepezil, respectively, ranges from 1.2 to 1.5 in the r

159 This study tests the hypothesis that donepezil reverses AIE-induced neuroimmune, and epigenet

160 The adjusted HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1

161 omized clinical trials, including at least 1 donepezil, rivastigmine, or galantamine treatment arm in

162 Cohort 2 compared memantine with donepezil, rivastigmine, or galantamine using the preval

163 utoff values used by regulatory agencies for donepezil, sertraline, norsertraline, and trazodone acro

164 try, we observed increasing tissue levels of donepezil, sertraline, norsertraline, citalopram, trazod

165 No correlations were found between the (11)C-donepezil signal and disease duration, severity of const

166 loss of cardiac MIBG signal and 11C-colonic donepezil signal followed by loss of putaminal FDOPA upt

167 econdary loss of cardiac MIBG signal and 11C-donepezil signal.

168 l, as compared to vehicle and lower doses of donepezil, significantly reduced brain tissue soluble Ab

169 Compared to donepezil, six showed equal/better synaptic protection i

170 tinum ratios (P < 10-5, ANOVA) and colon 11C-donepezil standard uptake values (P = 0.008, ANOVA).

171 rs was not lower among patients treated with donepezil than among those given placebo.

172 Although donepezil therapy was associated with a lower rate of pr

173 iodistribution and kinetic analyses of (11)C-donepezil time-activity curves were assessed with dynami

174 nded, placebo-controlled, phase III trial of donepezil to confirm these favorable results.

175 n subjects with the cholinesterase inhibitor donepezil (trade name: Aricept) and measured the effects

176 At endpoint, the donepezil-treated patients had significantly smaller mea

177 ate concentration tended to be higher in the donepezil-treated patients than in the patients who rece

178 ), a selective 5-HT6 receptor antagonist, in donepezil-treated patients with moderate Alzheimer's dis

179 Idalopirdine improved cognitive function in donepezil-treated patients with moderate Alzheimer's dis

180 s pailldus, and inferior frontal gyrus after donepezil treatment (p < 0.001).

181 These effects were reversed by donepezil treatment in adulthood.

182 verall gray matter (GM) volume changes after donepezil treatment in MCI, which is a prodromal phase o

183 ave demonstrated the symptomatic efficacy of donepezil treatment in patients with AD, the effects of

184 structures, and thus it remains unknown how donepezil treatment influences the volume change over th

185 Decisions to stop or continue donepezil treatment should be informed by potential risk

186 Donepezil treatment significantly enhanced the response

187 nance imaging (MRI) before and after 6-month donepezil treatment.

188 SE in patients with MCI improved by 8% after donepezil treatment.

189 Three donepezil, two galantamine, one rivastigmine, and two me

190 In contrast, tacrine and donepezil, typical AChE inhibitors, could not prevent sy

191 l abscesses was PET-scanned to explore (11)C-donepezil uptake in infections.

192 A linear correlation was seen between (11)C-donepezil volumes of distribution and standardized uptak

193 rrence rates of major depression of 44% with donepezil vs 12% with placebo (likelihood ratio = 4.91;

194 potentiate nAChR-mediated responses, whereas donepezil was a reasonably potent inhibitor of nicotine-

195 The cholinesterase inhibitor donepezil was administered to normal healthy human subje

196 lzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that ex

197 poprotein E epsilon4 alleles, the benefit of donepezil was evident throughout the three-year follow-u

198 Peripheral metabolization of (11)C-donepezil was low (>90% unchanged ligand at 60 min).

199 Finally, the analgesic effect of donepezil was markedly reduced by a microinjection of th

200 In addition, perceptual learning with donepezil was more selective to the trained direction of

201 In this 12-week trial, donepezil was not more effective than placebo in treatin

202 Donepezil was not significantly superior to placebo in t

203 emission tomography tracer 5-[(11)C]-methoxy-donepezil was recently validated for imaging acetylcholi

204 Donepezil was tested in a double-blind, placebo-controll

205 Rivastigmine, but not donepezil, was associated with greater risk of adverse e

206 ); however, significant differences favoring donepezil were observed for memory (recognition, P = .02

207 No major adverse effects of donepezil were observed, but it had an unpredicted negat

208 an acetylcholinesterase inhibitor treatment (donepezil) when compared to a placebo control group.

209 compounds (e.g. physostigmine, rivastigmine, donepezil) which are able to inhibit in a reversible way

210 Cohort 1 compared patients prescribed donepezil with those prescribed rivastigmine or galantam

211 l of these AIE effects were also reversed by donepezil, with the exception of HMGB1.

212 without memantine, 42 [58%] who discontinued donepezil without memantine, 41 [54%] who discontinued d

213 l groups (36 [49%] in patients who continued donepezil without memantine, 42 [58%] who discontinued d

214 patients were randomly assigned to continue donepezil without memantine, 73 (25%) to discontinue don

215 l without memantine, 73 (25%) to discontinue donepezil without memantine, 76 (26%) to discontinue don

216 10 mg per day without memantine, discontinue donepezil without memantine, discontinue donepezil and s

217 etermine whether long-term administration of donepezil would slow amyloid plaque deposition or confer